ELOX — Eloxx Pharmaceuticals Cashflow Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $0.67m
Annual cashflow statement for Eloxx Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -47.2 | -50.9 | -34.6 | -66.7 | -36.1 |
Depreciation | |||||
Non-Cash Items | 13.4 | 11.6 | 9.24 | 31.8 | 3.64 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 2.22 | -0.644 | -3.4 | -1.03 | -0.118 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -31.4 | -39.4 | -28.2 | -35 | -31.8 |
Capital Expenditures | -0.235 | -0.04 | — | -0.089 | -0.066 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.082 | -33.5 | 33.8 | 2.15 | 0 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.317 | -33.5 | 33.8 | 2.06 | -0.066 |
Financing Cash Flow Items | 2.17 | -1.25 | 0.277 | 2.56 | 8.81 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 56.2 | 46.8 | -3.44 | 50.8 | 8.81 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 24.5 | -26.1 | 2.19 | 17.8 | -23.1 |